Cognition Therapeutics (CGTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.73, -5.66% vs the prior close of $0.78.
- Volume 687.70K shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CGTX slides 5.7% to $0.73, a 6-month low, 7 down days in a row. Closed at $0.73, -5.66% vs the prior close of $0.78. Day range $0.72–$0.77, opened at $0.76.
CGTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CGTX slides 5.7% to $0.73, a 6-month low, 7 down days in a row
- Closed at $0.73, -5.66% vs the prior close of $0.78. Day range $0.72–$0.77, opened at $0.76.
- Volume was 687.70K shares, 1.3x its 50-day average of 525.76K.
- Price is -25.2% vs its 50-day average ($0.98) and -33.7% vs its 200-day average ($1.10).
- 52-week range $0.55–$2.00; today's close sits at 13% of that range, 63.4% below the 52-week high.
- That makes 7 straight losses.
Oct 14, 2026 — CGTX slides 3.1% to $0.78, a 6-month low, 6 down days in a row
- Closed at $0.78, -3.12% vs the prior close of $0.80. Day range $0.77–$0.81, opened at $0.80.
- Volume was 520.80K shares, 1.0x its 50-day average of 530.02K.
- Price is -21.2% vs its 50-day average ($0.99) and -29.9% vs its 200-day average ($1.11).
- 52-week range $0.55–$2.00; today's close sits at 16% of that range, 61.1% below the 52-week high.
- That makes 6 straight losses.
Oct 13, 2026 — CGTX slides 6.4% to $0.80, a 6-month low on 8.1x normal volume
- Closed at $0.80, -6.42% vs the prior close of $0.86. Day range $0.77–$0.93, opened at $0.90.
- Volume was 3.76M shares, 8.1x its 50-day average of 461.37K — unusually heavy trading.
- Price is -19.0% vs its 50-day average ($0.99) and -27.9% vs its 200-day average ($1.11).
- 52-week range $0.55–$2.00; today's close sits at 17% of that range, 59.9% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — CGTX dips 2.3% to $0.86, a 6-month low, 4 down days in a row
- Closed at $0.86, -2.28% vs the prior close of $0.88. Day range $0.83–$0.90, opened at $0.87.
- Volume was 413.30K shares, 0.9x its 50-day average of 461.25K.
- Price is -13.6% vs its 50-day average ($0.99) and -23.1% vs its 200-day average ($1.11).
- 52-week range $0.55–$2.05; today's close sits at 20% of that range, 58.2% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — CGTX dips 2.0% to $0.88, a 6-month low, 3 down days in a row
- Closed at $0.88, -2.01% vs the prior close of $0.89. Day range $0.87–$0.92, opened at $0.90.
- Volume was 316.90K shares, 0.7x its 50-day average of 460.10K.
- Price is -11.7% vs its 50-day average ($0.99) and -21.5% vs its 200-day average ($1.12).
- 52-week range $0.55–$2.05; today's close sits at 22% of that range, 57.2% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — CGTX slides 4.5% to $0.89
- Closed at $0.89, -4.48% vs the prior close of $0.94. Day range $0.89–$0.95, opened at $0.95.
- Volume was 452.70K shares, 1.0x its 50-day average of 458.06K.
- Price is -9.9% vs its 50-day average ($0.99) and -20.2% vs its 200-day average ($1.12).
- 52-week range $0.55–$2.05; today's close sits at 23% of that range, 56.3% below the 52-week high.
Oct 7, 2026 — CGTX dips 0.3% to $0.94
- Closed at $0.94, -0.32% vs the prior close of $0.94. Day range $0.93–$0.96, opened at $0.93.
- Volume was 201.60K shares, 0.4x its 50-day average of 463.51K — lighter than usual.
- Price is -5.7% vs its 50-day average ($0.99) and -16.7% vs its 200-day average ($1.12).
- 52-week range $0.55–$2.05; today's close sits at 26% of that range, 54.3% below the 52-week high.
Oct 6, 2026 — CGTX ends flat (+0.2%) to $0.94, 3 up days in a row
- Closed at $0.94, +0.21% vs the prior close of $0.94. Day range $0.93–$0.96, opened at $0.94.
- Volume was 329.50K shares, 0.7x its 50-day average of 465.15K.
- Price is -5.4% vs its 50-day average ($0.99) and -16.6% vs its 200-day average ($1.13).
- 52-week range $0.55–$2.05; today's close sits at 26% of that range, 54.1% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — CGTX rises 1.4% to $0.94
- Closed at $0.94, +1.41% vs the prior close of $0.93. Day range $0.92–$0.97, opened at $0.94.
- Volume was 326.80K shares, 0.7x its 50-day average of 467.64K.
- Price is -5.6% vs its 50-day average ($0.99) and -17.0% vs its 200-day average ($1.13).
- 52-week range $0.55–$2.05; today's close sits at 26% of that range, 54.2% below the 52-week high.
Oct 2, 2026 — CGTX jumps 3.8% to $0.93
- Closed at $0.93, +3.82% vs the prior close of $0.89. Day range $0.90–$0.93, opened at $0.92.
- Volume was 300.10K shares, 0.6x its 50-day average of 468.14K.
- Price is -6.9% vs its 50-day average ($0.99) and -18.3% vs its 200-day average ($1.13).
- 52-week range $0.55–$2.05; today's close sits at 25% of that range, 54.9% below the 52-week high.
CGTX latest news & SEC filings
Every SEC filing by or about CGTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.93M (prior year -$6.73M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.04 (prior year -$0.11) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CGTX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.59% (largest 7.2%).
- Liquidity: about 600.74K shares (≈$440.34K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.73 vs a range of $0.55–$2.00 (13% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 3 open-market buys, 0 sales; latest: Anthony Caggiano bought 10,000 shares on Apr 16, 2026.
- Latest filings: 10-Q Aug 7, 2026; 8-K Aug 6, 2026; 8-K Jun 24, 2026.
- Share count: 95.09M shares outstanding (Aug 4, 2026), +29.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CGTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.76 | 0.77 | 0.72 | 0.73 | 687.70K |
| Oct 14, 2026 | 0.80 | 0.81 | 0.77 | 0.78 | 520.80K |
| Oct 13, 2026 | 0.90 | 0.93 | 0.77 | 0.80 | 3.76M |
| Oct 12, 2026 | 0.87 | 0.90 | 0.83 | 0.86 | 413.30K |
| Oct 9, 2026 | 0.90 | 0.92 | 0.87 | 0.88 | 316.90K |
| Oct 8, 2026 | 0.95 | 0.95 | 0.89 | 0.89 | 452.70K |
| Oct 7, 2026 | 0.93 | 0.96 | 0.93 | 0.94 | 201.60K |
| Oct 6, 2026 | 0.94 | 0.96 | 0.93 | 0.94 | 329.50K |
| Oct 5, 2026 | 0.94 | 0.97 | 0.92 | 0.94 | 326.80K |
| Oct 2, 2026 | 0.92 | 0.93 | 0.90 | 0.93 | 300.10K |
| Oct 1, 2026 | 0.98 | 0.99 | 0.89 | 0.89 | 791.70K |
| Sep 30, 2026 | 0.98 | 0.98 | 0.96 | 0.96 | 386.10K |
| Sep 29, 2026 | 0.96 | 0.98 | 0.93 | 0.95 | 525.10K |
| Sep 28, 2026 | 0.93 | 0.96 | 0.92 | 0.94 | 200.20K |
| Sep 25, 2026 | 0.98 | 0.98 | 0.93 | 0.94 | 540.00K |
| Sep 24, 2026 | 0.97 | 0.97 | 0.93 | 0.95 | 266.40K |
| Sep 23, 2026 | 1.00 | 1.01 | 0.95 | 0.95 | 563.30K |
| Sep 22, 2026 | 1.03 | 1.03 | 0.98 | 0.98 | 329.50K |
| Sep 21, 2026 | 1.05 | 1.08 | 1.00 | 1.00 | 769.80K |
| Sep 18, 2026 | 1.06 | 1.07 | 1.04 | 1.04 | 336.20K |
About Cognition Therapeutics
Cognition Therapeutics (CGTX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in PURCHASE, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1455365.
CGTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Advisors Gp, Llc Bios | Director | Jun 22, 2026 |
| Capital Management, Lp Bios | Director | Jun 22, 2026 |
| Fund I Qp, Lp Bios | Director | Jun 22, 2026 |
| Fund I, Lp Bios | Director | Jun 22, 2026 |
| Fund Ii Qp, Lp Bios | Director | Jun 22, 2026 |
| Fund Ii, Lp Bios | Director | Jun 22, 2026 |
| Memory Spv I, Lp Bios | Director | Jun 22, 2026 |
| Equity Partners Ii, Lp Bios | Director | Jun 22, 2026 |
| Equity Partners, Lp Bios | Director | Jun 22, 2026 |
| Aaron G.L. Fletcher | Director | Jun 22, 2026 |
| Jack A. Khattar | Director | Jun 22, 2026 |
| Brett P Monia | Director | Jun 22, 2026 |
| Ellen B Richstone | Director | Jun 22, 2026 |
| Lisa Ricciardi | CEO & President | Apr 20, 2026 |
| Peggy Wallace | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Anthony Caggiano | Chief Medical Officer | Apr 20, 2026 |
| John Brendan Doyle | Chief Financial Officer | May 4, 2026 |
| Lisa Ricciardi | CEO & President | Apr 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 16, 2026 | Anthony Caggiano | Buy | 10,000 | $1.11 |
| Apr 16, 2026 | Lisa Ricciardi | Buy | 9,175 | $1.10 |
| Apr 16, 2026 | John Brendan Doyle | Buy | 10,000 | $1.13 |
CGTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-23.49M | -0.32 | $-24.59M |
| Dec 31, 2024 | — | $-33.97M | -0.86 | $-28.47M |
| Dec 31, 2023 | — | $-25.79M | -0.86 | $-16.02M |
| Dec 31, 2022 | — | $-21.40M | -0.91 | $-18.53M |
| Dec 31, 2021 | — | $-11.72M | -3.13 | $-3.63M |
Latest balance sheet: total assets $38.90M, total liabilities $5.87M, cash $34.01M (as of Jun 30, 2026).
CGTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $1.13 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.16 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $1.08 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.66 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $0.68 |
| May 7, 2025 | 8-K Item 2.02 (results) | $0.35 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $0.43 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $0.54 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CGTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.